An androgen therapy, it works by blocking the production of testosterone which prostate cancer needs to grow. It is expected to be available to patients on the NHS within three months of the ...

The spacer reduces life-changing effects of radiation therapy such as rectal pain and erectile dysfunction There can be few symptoms of prostate cancer in the early stages, and because of its ...

Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light from the UK Medicines and Healthcare products Regulatory Agency (MHRA).